The California Biotech Law Blog reported that the outlook for biotech in 2012 was expected to remain dreary, and that companies would continue to focus on acquisitions over IPOs in the following blog post:
The California Biotech Law Blog looked at the issue of how patent reform would affect the biotech industry in the following blog post link:
The Silicon Valley IP Licensing Law Blog discussed the passage of the Patent Reform Bill and explored its significance to Silicon Valley in the following blog post link below:
The California Biotech Law Blog discussed the constitutional arguments at issue in the challenge posed to the health care reform bill in the following blog post:
How is the biotech industry reacting to the passage of health care reform? The California Biotech Law Blog explored the industry reaction in the following blog post:
The Prinz Law Office is pleased to announce that the California Biotech Law Blog has been named to a list of Top 50 Biotech Blogs.
The California Biotech Law Blog announced that the blog has been recognized as a top 50 biotech blog in the following blog post:
Patrick Reilly of IP Society interviewed Silicon Valley biotech licensing lawyer Kristie Prinz, as reported in the following blog post:
The California Biotech Law Blog reported on The SciTech Lawyer’s profile story on Silicon Valley Biotech Transactions Lawyer Kristie Prinz in the following blog post:
Do poster presentations jeopardize a tech transfer office’s commercialization efforts? The California Biotech Law Blog reported on Technology Transfer Tactics’ interview of Silicon Valley Lawyer Kristie Prinz on this issue at the following blog post:
The Seventh Circuit Court of Appeals has ruled in favor of WARF in its licensing dispute with Xenon Pharmaceuticals, as reported by the California Biotech Law Blog in the following blog post:
The California Biotech Law Blog explored the issues delaying SBIR reauthorization in the following blog post: